Homeward Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Minneapolis value-based care company delivering primary care to rural Americans via in-home visits and telehealth; targets provider-shortage areas where patients face long distances to care.
About
Homeward Health is a Minneapolis-based healthcare company that provides primary care and chronic disease management to rural populations who lack access to local providers, using a hybrid model combining in-home clinical visits, telehealth, and community-based care navigators. Rural Americans face significantly worse health outcomes than urban populations due to provider shortages, long travel distances to care, and lower rates of insurance coverage. Homeward deploys care teams that travel to rural areas to see patients in their homes and community settings, supplemented by telehealth for follow-up and specialist access, creating continuity of care that most rural residents cannot access. The company operates under value-based care contracts that align incentives around keeping patients healthy and out of the hospital rather than fee-for-service volume. Founded in 2021, Homeward raised over $50M from investors including General Catalyst, Tiger Global, and Andreessen Horowitz Bio. The company targets the significant rural health gap and the growing population of Medicare Advantage plans seeking to improve outcomes and reduce costs for rural beneficiaries.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.